ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$25.97
0.77 (3.06%)
▲
5d:
+9.49%
30d:
+24.32%
90d:
+16.35%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ACAD is 8.4% above its trading range ($23.95). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ACAD is 8.4% above its trading range ($23.95). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$42.97
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.68
2.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $25.97, which is considered extended relative to its 30-day fair value range of $20.81 to $23.95. The stock's valuation (Forward PE: 29.4) is in line with its historical norms (27.2). At these levels, the market is pricing in 2.7% annual earnings growth.
Technical Outlook: Technically, ACAD is showing sideways momentum. Immediate support is located at $21.20, while resistance sits at $27.31. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ACAD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $32.30 (+24.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACAD is showing sideways momentum. Immediate support is located at $21.20, while resistance sits at $27.31. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ACAD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $32.30 (+24.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$20.81 -
$23.95
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
Protect Your Profits
ACAD is technically overbought (RSI 78). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+8.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 24.4% below Wall St target ($32.30)
- BULLISH: Expecting earnings turnaround to 2.7% growth with 9.7% revenue growth
- CAUTION: Extended 8.4% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$20.81 -
$23.95
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$21.20
Resistance Level
$27.31
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
29.42
Wall Street Target
$32.30
(+24.4%)
Revenue Growth (YoY)
9.7%
Earnings Growth (YoY)
-81.8%
Profit Margin
34.3%
Valuation Premium vs History
+2.7% premium
PE vs Historical
29.4 vs 27.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.7%
(market-implied from PE analysis)
1-Year Target
$26.67
(+3%)
2-Year Target
$27.39
(+6%)
3-Year Target
$28.13
(+8%)
3-Yr Target (if PE normalizes)
(PE: 29→27)
PE COMPRESSION
$26.01
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 29.4, Growth: 131.0%)
$87.65
(+238%)
Base:
(SPY PE: 21.8, Growth: 131.0%)
$64.89
(+150%)
Bear:
(PE: 18.5, Growth: 131.0%)
$55.15
(+112%)
📈
Valuation based on Current Earnings
Trailing PE: 11.40 | Current EPS (TTM): $2.21
Bull Case
$13.86
(-47%)
Analyst growth -50.0%, PE expands to 12.5
Base Case
$12.60
(-52%)
Market implied -50.0%, PE stable at 11.4
Bear Case
$17.14
(-34%)
Severe decline -20.0%, PE contracts to 9.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 5:33 PM ET
Data refreshes hourly during market hours. Next update: 6:33 PM
Data refreshes hourly during market hours. Next update: 6:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Jennifer J Rhodes
SELL
6950 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
